Cutting-edge EU-funded project METASTRA unites an interdisciplinary team of experts to spearhead a transformative approach to revolutionize fracture risk assessment and personalized treatment for cancer patients with vertebral metastases. A groundbreaking initiative, METASTRA is set to transform the way clinicians
Each year, the BRAINTEASER project organizes an open evaluation challenge, called iDPP@CLEF (Intelligent Disease Progression Prediction), to involve research groups from academia and industry in the assessment of the performance of their AI algorithms to predict the progression of ALS
In Silico Trials, the use of computational modelling & simulation in the development and regulatory assessments of biomedical products is an emerging practice in the biomedical industry. While the first technical standards, such as the ASME VV-40:2018, are appearing, there
BRAINTEASER mid-term workshop took place on 28 February 2023 in the prestigious location of the University of Padua Botanical Garden, Italy and was attended by almost 80 participants. The organization of the event came at the end of the first phase of
Following the 2021 launch of Project Optimus by the Oncology Center of Excellence and an extensive workshop on the topic, in January 2023 the FDA released a draft guidance for industry entitled “Optimizing the Dosage of Human Prescription Drugs and
Data science and artificial intelligence for supporting the care and cure of amyotrophic lateral sclerosis and multiple sclerosis patients is the title of the BRAINTEASER Mid Term Workshop, to be held on February 28th, in the prestigious location of the
An in silico clinical trial is also known as a virtual clinical trial. It is a method used to develop drugs and medical devices using computer simulation, powered by artificial intelligence. This method allows testing the drug samples in virtual
BRAINTEASER takes part in the Brain Innovation Days 2022 The second edition of the Brain Innovation Days took place on 11-12 October 2022 in Brussels (Belgium) and featured BRAINTEASER as one of the exhibitors in the Innovation Hall. This year’s edition of the event
The use of in silico trials is expected to play an increasingly important role in the development and regulatory evaluation of new drugs and medical devices. One of the advantages that in silico approaches offer is the possibility to test
BRAINTEASER contribution to the DHSS 2022 The Digital Health Society Summit 4th edition, that took place virtually on October 4th and 5th 2022, has seen the contribution of BRAINTEASER in two relevant panel discussions: “How do you maximise the use of Health
The scope of this white paper is to clarify the different definitions of Digital Twin, Digital Patient, Virtual Patient and Synthetic Control Arm in the Pharma and MedTech fields. Please read more about it here: https://insilicotrials.com/white-papers/
An Interview with Nicola Ferro: Discovering The iDPP@CLEF Challenge 2022 For those of us who don’t know much about CLEF, can you tell us more about what it comprises and how the iDPP@CLEF Challenge plays a role? Of